LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder

May 13, 2015, 19:00 ET from LCS Group, LLC

NEW HAVEN, Conn., May 13, 2015 /PRNewswire/ -- LCS Group, LLC announced today its exclusive license from Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 and U.S. Patent Application No. 14/464,249, both titled "Method of Treating Binge Eating Disorder" ("BED").   LCS Group's exclusive license is part of a unique strategic collaboration with the intellectual property's owner, Lucerne Biosciences, with further details of the collaboration soon to be announced.  LCS Group's commercialization of the '813 Patent and '249 Application is planned through Shire US Inc.'s national marketing campaign of the drug lisdexamfetamine dimesylate ("LDX") to treat BED. 

The '813 Patent's and '249 Application's claims both encompass the use of LDX to treat BED, with the '249 Application featuring methods that include "informing a patient that LDX is therapeutically effective for treating BED," as by "a flyer, an advertisement, a package insert for a pharmaceutical product, printed labeling, an internet website, an internet pop-up window, or information on a compact disk, DVD, or an audio recording."

"This exclusive license to commercialize Lucerne Biosciences' intellectual property for a drug recently approved by the FDA to treat BED and currently marketed by Shire for that purpose is an important step forward in bringing much needed public attention to the proper diagnosis and treatment of BED.   Public misconceptions on diagnosing and treating of BED have abounded, even among healthcare professionals and the pharmaceutical industry.  LCS Group has taken unprecedented actions to publicly clarify them through its novel commercialization platform, collaboration with Lucerne Biosciences, and even Shire's own solid marketing efforts. With LDX the first and currently only FDA approved treatment for moderate to severe adult BED, there's no better time than now to educate the public-at-large on how to properly diagnose and treat this serious disorder," said Louis Sanfilippo, M.D., CEO of LCS Group.

About LCS Group, LLC

LCS Group is a privately-held intellectual property development and commercialization company focused on novel therapies to help people suffering from psychiatric disorders and other behavioral health problems.

About BED 

BED is a serious eating disorder.  BED's DSM-V® criteria include eating unusually large amounts of food in a discrete period of time (i.e., within a 2 hour period) and a sense of lack of control over eating during the episode with binge eating episodes associated with at least three (or more) of the following: eating much more rapidly than normal; eating until feeling uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed or very guilty after overeating.  Additionally, marked distress regarding the binge eating is present and the binge eating occurs, on average, at least once a week for 3 months; also, the binge eating does not occur exclusively during the course of bulimia nervosa or anorexia nervosa.

About Lisdexamfetamine Dimesylate

Lisdexamfetamine dimesylate (l-lysine-d-amphetamine) is an amphetamine prodrug approved by the FDA to treat moderate to severe BED in adults.  LDX is also FDA approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Inquires/Business Development

Inquiries about potential business opportunities (i.e., a license to the '813 Patent and/or '249 Patent Application) are best emailed to lsanfilippo@lcsgroupllc.com.  Inquiries about potential "class (legal) actions" (i.e., "class of Shire Plc shareholder") are best emailed to: lsanfilippo@lucernebiollc.com.  Supplemental information that highlights the value proposition for potential business opportunities, as well as identifies prospective members of a "class" for a potential "class (legal) action," is available in a PDF titled "The Patent 813 Story, Part II" at: http://www.4shared.com/download/LpqSz0PYce/The_Patent_813_Story_Part_II.pdf?lgfp=3000.  The '813 Patent is available in PDF at: http://www.4shared.com/download/XNMle7iGba/US_Patent_No_8318813.pdf?lgfp=3000.

Media Contact:
Louis Sanfilippo, MD
CEO, LCS Group, LLC
203-362-8919

U.S. Patent No. 8,318,813/Method of Treating Binge Eating Disorder
U.S. Patent Application No. 14/464,249/ Method of Treating Binge Eating Disorder

SOURCE LCS Group, LLC



RELATED LINKS

http://www.lcsgroupllc.com